Skip to content

Commit

Permalink
Merge pull request #561 from monarch-initiative/issue-543-pharm
Browse files Browse the repository at this point in the history 
add pharmacotherapy terms
  • Loading branch information
Leigh Carmody authored May 16, 2023
2 parents a4bece2 + eb32983 commit d4677a9
Show file tree
Hide file tree
Showing 7 changed files with 116 additions and 20 deletions.
11 changes: 9 additions & 2 deletions src/ontology/maxo-edit.owl
View file
Original file line number Diff line number Diff line change
Expand Up @@ -3716,7 +3716,7 @@ AnnotationAssertion(<http://www.geneontology.org/formats/oboInOwl#hasExactSynony
AnnotationAssertion(rdfs:label <http://purl.obolibrary.org/obo/MAXO_0000258> "glycemic agent therapy"@en)
SubClassOf(<http://purl.obolibrary.org/obo/MAXO_0000258> <http://purl.obolibrary.org/obo/MAXO_0000175>)

# Class: <http://purl.obolibrary.org/obo/MAXO_0000259> (therapeutic insulin treatment)
# Class: <http://purl.obolibrary.org/obo/MAXO_0000259> (<http://purl.obolibrary.org/obo/MAXO_0000259>)

AnnotationAssertion(Annotation(<http://www.geneontology.org/formats/oboInOwl#hasDbXref> "NCIT:C581") <http://purl.obolibrary.org/obo/IAO_0000115> <http://purl.obolibrary.org/obo/MAXO_0000259> "A synthetic or animal-derived form of insulin used in the treatment of diabetes mellitus. Therapeutic insulin is formulated to be short-, intermediate- and long-acting in order to individualize an insulin regimen according to individual differences in glucose and insulin metabolism. Therapeutic insulin may be derived from porcine, bovine or recombinant sources. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats and has anabolic effects on many types of tissues.")
AnnotationAssertion(dce:date <http://purl.obolibrary.org/obo/MAXO_0000259> "2019-01-22T20:33:51Z"^^xsd:dateTime)
Expand All @@ -3725,7 +3725,7 @@ AnnotationAssertion(<http://www.geneontology.org/formats/oboInOwl#hasDbXref> <ht
AnnotationAssertion(<http://www.geneontology.org/formats/oboInOwl#hasExactSynonym> <http://purl.obolibrary.org/obo/MAXO_0000259> "insulin drug treatment")
AnnotationAssertion(<http://www.geneontology.org/formats/oboInOwl#hasExactSynonym> <http://purl.obolibrary.org/obo/MAXO_0000259> "insulin therapy")
AnnotationAssertion(<http://www.geneontology.org/formats/oboInOwl#hasExactSynonym> <http://purl.obolibrary.org/obo/MAXO_0000259> "therapeutic insulin preparations treatment")
AnnotationAssertion(rdfs:label <http://purl.obolibrary.org/obo/MAXO_0000259> "therapeutic insulin treatment"@en)
AnnotationAssertion(<http://www.geneontology.org/formats/oboInOwl#hasExactSynonym> <http://purl.obolibrary.org/obo/MAXO_0000259> "therapeutic insulin therapy")
SubClassOf(<http://purl.obolibrary.org/obo/MAXO_0000259> <http://purl.obolibrary.org/obo/MAXO_0000572>)

# Class: <http://purl.obolibrary.org/obo/MAXO_0000260> (central nervous system agent therapy)
Expand Down Expand Up @@ -11570,4 +11570,11 @@ AnnotationAssertion(<http://purl.obolibrary.org/obo/IAO_0000115> <http://purl.ob
AnnotationAssertion(<http://purl.obolibrary.org/obo/IAO_0000115> <http://purl.obolibrary.org/obo/MAXO_0001338> "Treatment with a drug or agent that activates GABAA receptor signaling.")
AnnotationAssertion(<http://purl.obolibrary.org/obo/IAO_0000115> <http://purl.obolibrary.org/obo/MAXO_0001339> "Treatment with a drug or agent that activates GABAB receptor signaling.")
AnnotationAssertion(<http://purl.obolibrary.org/obo/IAO_0000115> <http://purl.obolibrary.org/obo/MAXO_0001340> "Treatment with a drug or agent that inhibits GABAA receptor signaling.")
AnnotationAssertion(<http://purl.obolibrary.org/obo/IAO_0000115> <http://purl.obolibrary.org/obo/MAXO_0001469> "Use of a drug or agent that inhibits farnesyltransferase.")
AnnotationAssertion(<http://purl.obolibrary.org/obo/IAO_0000115> <http://purl.obolibrary.org/obo/MAXO_0001470> "Use of a drug or agent that inhibits matrix metalloprotease inhibitor.")
AnnotationAssertion(<http://purl.obolibrary.org/obo/IAO_0000115> <http://purl.obolibrary.org/obo/MAXO_0001471> "Treatment with a topical cream that is used to treat psoriasis.")
AnnotationAssertion(<http://purl.obolibrary.org/obo/IAO_0000115> <http://purl.obolibrary.org/obo/MAXO_0001473> "Treatment with a diuretic to treat hypertension or edema.")
AnnotationAssertion(<http://purl.obolibrary.org/obo/IAO_0000115> <http://purl.obolibrary.org/obo/MAXO_0001474> "Treatment with thyroid hormone or drugs replicating thyroid hormone to maintain a normally functioning thyroid.")
AnnotationAssertion(<http://purl.obolibrary.org/obo/IAO_0000115> <http://purl.obolibrary.org/obo/MAXO_0001475> "Treatment with a class of medicines inhibit sodium-glucose cotransporter-2. Drugs are used with diet and exercise to lower blood sugar in adults with type 2 diabetes.")
AnnotationAssertion(<http://purl.obolibrary.org/obo/IAO_0000115> <http://purl.obolibrary.org/obo/MAXO_0001476> "Treatment with an activator to the somatostatin receptor.")
)
7 changes: 7 additions & 0 deletions src/ontology/reports/maxo-base.owl-obo-report.tsv
View file
Original file line number Diff line number Diff line change
Expand Up @@ -527,6 +527,13 @@ WARN missing_superclass MAXO:0001464 rdfs:subClassOf
WARN missing_superclass MAXO:0001465 rdfs:subClassOf
WARN missing_superclass MAXO:0001466 rdfs:subClassOf
WARN missing_superclass MAXO:0001467 rdfs:subClassOf
WARN missing_superclass MAXO:0001469 rdfs:subClassOf
WARN missing_superclass MAXO:0001470 rdfs:subClassOf
WARN missing_superclass MAXO:0001471 rdfs:subClassOf
WARN missing_superclass MAXO:0001473 rdfs:subClassOf
WARN missing_superclass MAXO:0001474 rdfs:subClassOf
WARN missing_superclass MAXO:0001475 rdfs:subClassOf
WARN missing_superclass MAXO:0001476 rdfs:subClassOf
WARN missing_superclass MAXO:0010004 rdfs:subClassOf
WARN missing_superclass MAXO:0010005 rdfs:subClassOf
WARN missing_superclass MAXO:0010006 rdfs:subClassOf
Expand Down
7 changes: 7 additions & 0 deletions src/ontology/reports/maxo-edit.owl-obo-report.tsv
View file
Original file line number Diff line number Diff line change
Expand Up @@ -527,6 +527,13 @@ WARN missing_superclass MAXO:0001464 rdfs:subClassOf
WARN missing_superclass MAXO:0001465 rdfs:subClassOf
WARN missing_superclass MAXO:0001466 rdfs:subClassOf
WARN missing_superclass MAXO:0001467 rdfs:subClassOf
WARN missing_superclass MAXO:0001469 rdfs:subClassOf
WARN missing_superclass MAXO:0001470 rdfs:subClassOf
WARN missing_superclass MAXO:0001471 rdfs:subClassOf
WARN missing_superclass MAXO:0001473 rdfs:subClassOf
WARN missing_superclass MAXO:0001474 rdfs:subClassOf
WARN missing_superclass MAXO:0001475 rdfs:subClassOf
WARN missing_superclass MAXO:0001476 rdfs:subClassOf
WARN missing_superclass MAXO:0010004 rdfs:subClassOf
WARN missing_superclass MAXO:0010005 rdfs:subClassOf
WARN missing_superclass MAXO:0010006 rdfs:subClassOf
Expand Down
11 changes: 8 additions & 3 deletions src/patterns/data/manual/pharmacotherapy_chemicalrole.tsv
View file
Original file line number Diff line number Diff line change
Expand Up @@ -135,10 +135,15 @@ MAXO:0001326 nicotinic acetylcholine receptor agonist therapy CHEBI:24431 chemic
MAXO:0001327 cholinergic antagonist therapy CHEBI:24431 chemical entity CHEBI:48873 cholinergic antagonist http://orcid.org/0000-0001-7941-2961 2023-02-23T11:00:00Z
MAXO:0001328 muscarinic antagonist therapy CHEBI:24431 chemical entity CHEBI:48876 muscarinic antagonist http://orcid.org/0000-0001-7941-2961 2023-02-23T11:00:00Z
MAXO:0001329 nicotinic antagonist therapy CHEBI:24431 chemical entity CHEBI:48878 nicotinic antagonist http://orcid.org/0000-0001-7941-2961 2023-02-23T11:00:00Z
MAXO:0001330 parasympatholytic therapy CHEBI:24431 chemical entity CHEBI:50370 parasympatholytic http://orcid.org/0000-0001-7941-2961 2023-02-23T11:00:00Z
MAXO:0001331 dopaminergic modifying agent therapy CHEBI:24431 chemical entity CHEBI:48560 dopaminergic agent http://orcid.org/0000-0001-7941-2961 2023-02-23T11:00:00Z
MAXO:0001330 parasympatholytic therapy CHEBI:24431 chemical entity CHEBI:50370 parasympatholytic http://orcid.org/0000-0001-7941-2961 2023-02-23T11:00:00Z dopaminergic modifying agent therapy
MAXO:0001331 dopaminergic agent therapy CHEBI:24431 chemical entity CHEBI:48560 dopaminergic agent http://orcid.org/0000-0001-7941-2961 2023-02-23T11:00:00Z
MAXO:0001332 dopamine agonist therapy CHEBI:24431 chemical entity CHEBI:51065 dopamine agonist http://orcid.org/0000-0001-7941-2961 2023-02-23T11:00:00Z
MAXO:0001333 dopamine receptor D1 agonist therapy CHEBI:24431 chemical entity CHEBI:131795 dopamine receptor D1 agonist http://orcid.org/0000-0001-7941-2961 2023-02-23T11:00:00Z
MAXO:0001334 dopamine uptake inhibitor therapy CHEBI:24431 chemical entity CHEBI:51039 dopamine uptake inhibitor http://orcid.org/0000-0001-7941-2961 2023-02-23T11:00:00Z
MAXO:0001335 dopaminergic antagonist agent therapy CHEBI:24431 chemical entity CHEBI:48561 dopaminergic antagonist http://orcid.org/0000-0001-7941-2961 2023-02-23T11:00:00Z
MAXO:0001421 keratolytic agent therapy CHEBI:24431 chemical entity CHEBI:50176 keratolytic drug http://orcid.org/0000-0001-7941-2961 2023-03-31T11:00:00Z
MAXO:0001421 keratolytic agent therapy CHEBI:24431 chemical entity CHEBI:50176 keratolytic drug http://orcid.org/0000-0001-7941-2961 2023-03-31T11:00:00Z
MAXO:0001469 farnesyltransferase inhibitor agent therapy CHEBI:24431 chemical entity CHEBI:64133 EC 2.5.1.58 (protein farnesyltransferase) inhibitor http://orcid.org/0000-0003-4830-7530 2023-05-15T11:00:00Z farnesyltransferase inhibitor treatment
MAXO:0001470 MMP inhibitor agent therapy CHEBI:24431 chemical entity CHEBI:50664 matrix metalloprotease inhibitor http://orcid.org/0000-0001-7941-2961 2023-05-15T11:00:00Z
MAXO:0001474 thyroid hormone therapy CHEBI:24431 chemical entity CHEBI:60311 thyroid hormone http://orcid.org/0000-0001-7941-2961 2023-05-15T11:00:00Z
MAXO:0001475 sodium-glucose cotransporter-2 inhibitor therapy CHEBI:24431 chemical entity CHEBI:73273 sodium-glucose transport protein subtype 2 inhibitor http://orcid.org/0000-0001-7941-2961 2023-05-15T11:00:00Z
MAXO:0001476 somatostatin recepter agonist therapy CHEBI:24431 chemical entity CHEBI:177023 somatostatin receptor agonist http://orcid.org/0000-0001-7941-2961 2023-05-15T11:00:00Z
5 changes: 4 additions & 1 deletion src/patterns/data/manual/pharmacotherapy_chemicalsubstance.tsv
View file
Original file line number Diff line number Diff line change
Expand Up @@ -8,4 +8,7 @@ MAXO:0000203 tetracycline therapy CHEBI:24431 chemical entity CHEBI:27902 tetrac
MAXO:0000220 glucocorticicoid agent therapy CHEBI:24431 chemical entity CHEBI:24261 glucocorticoid
MAXO:0000261 amphetamine agent therapy CHEBI:24431 chemical entity CHEBI:35338 amphetamines
MAXO:0000432 beta-lactam antibacterial agent therapy CHEBI:24431 chemical entity CHEBI:27933 beta-lactam antibiotic
MAXO:0009095 zinc therapy CHEBI:24431 chemical entity CHEBI:27363 zinc atom
MAXO:0009095 zinc therapy CHEBI:24431 chemical entity CHEBI:27363 zinc atom
MAXO:0000259 insulin treatment CHEBI:24431 chemical entity CHEBI:145810 insulin
MAXO:0001473 benzothiadiazine derivative therapy CHEBI:24431 chemical entity CHEBI:50265 benzothiadiazine http://orcid.org/0000-0001-7941-2961 2023-05-15T11:00:00Z
MAXO:0001471 tazarotene agent therapy CHEBI:24431 chemical entity CHEBI:32184 tazarotene http://orcid.org/0000-0001-7941-2961 2023-05-15T11:00:00Z
10 changes: 0 additions & 10 deletions src/patterns/data/todo/MAXO_availableIDs.txt
View file
Original file line number Diff line number Diff line change
@@ -1,15 +1,5 @@



MAXO:0001469
MAXO:0001470
MAXO:0001471
MAXO:0001472
MAXO:0001473
MAXO:0001474
MAXO:0001475
MAXO:0001476
MAXO:0001477
MAXO:0001478
MAXO:0001479
MAXO:0001480
Expand Down
Loading

0 comments on commit d4677a9

Please sign in to comment.